SCHEMBL1948780

SCHEMBL1948780

Cc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(C(=O)O)CC3Cc2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA1 Q09470 5/20 0.54
KCNAB1 Q14722 5/20 0.54
MAPT P10636 2/20 0.46
TP53 P04637 1/20 0.46
ALDH1A1 P00352 5/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
THRB P10828 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 2/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
LIMK2 P53671 1/20 0.43
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP7 P09237 1/20 0.42
MMP9 P14780 1/20 0.42
MMP12 P39900 1/20 0.42
MMP14 P50281 1/20 0.42
MMP15 P51511 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1945841 0.92 KCNA1 (0.53) KCNA1KCNAB1
SCHEMBL6163822 0.76 KCNA1 (0.72) KCNA1KCNAB1MAPTTP53ALDH1A1
SCHEMBL1948779 0.75 KCNA1 (0.65) KCNA1KCNAB1MAPTTP53ALDH1A1
SCHEMBL1944493 0.73 KCNA1 (0.92) KCNA1KCNAB1MAPTTP53ALDH1A1
SCHEMBL1946008 0.71 KCNA1 (1.00) KCNA1KCNAB1MAPTTP53ALDH1A1
SCHEMBL1946003 0.70 KCNA1 (1.00) KCNA1KCNAB1ALDH1A1SMN1; SMN2LMNA
SCHEMBL10564280 0.67 KCNA1 (0.59) KCNA1KCNAB1TP53ALDH1A1SMN1; SMN2
SCHEMBL1945839 0.66 KCNA1 (0.63) KCNA1KCNAB1
SCHEMBL15352654 0.66 TACR3 (0.43) ALDH1A1L3MBTL1GAAMEN1KMT2A
SCHEMBL9052963 0.66 TACR3 (0.43) ALDH1A1L3MBTL1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110130383-A1 Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases LECTUS THERAPEUTICS LIMITED (GB) 2011-06-02 US disclosed
US-20090318423-A1 Ion Channel Modulators & Uses Thereof LECTUS THERAPEUTICS LIMITED (GB) 2009-12-24 US disclosed
EP-2069309-A1 ION CHANNEL MODULATORS&USES THEREOF Lectus Therapeutics Limited (GB) 2009-06-17 EP disclosed
EP-2066317-A2 USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES Lectus Therapeutics Limited (GB) 2009-06-10 EP disclosed
WO-2008038053-A1 ION CHANNEL MODULATORS & USES THEREOF LECTUS THERAPEUTICS LIMITED (GB) 2008-04-03 WO disclosed
WO-2008038051-A2 USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES LECTUS THERAPEUTICS LIMITED (GB) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318423-A1 Ion Channel Modulators & Uses Thereof KCNH3, KCNN3, KCNH2 KCNA1 26/4885KCNAB1 40/4885MAPT 4716/4885
US-20110130383-A1 Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases HCAR2, HCAR1, SCN7A KCNA1 167/4885KCNAB1 98/4885MAPT 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.